A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
INTEGRATED BIOPHARMA INC
INBP
$4M
Mkt Cap
$0.16
+0.00%
INTEGRATED BIOPHARMA INC (INBP) has a current P/E ratio of 8.0, compared to its historical median P/E of 3.8. The stock is currently considered Expensive based on its historical valuation range.
INTEGRATED BIOPHARMA INC (INBP) has a 5-year average return on invested capital (ROIC) of 11.4%. This indicates solid capital allocation.
INTEGRATED BIOPHARMA INC (INBP) has a market capitalization of $5M. It is classified as a small-cap stock.
INTEGRATED BIOPHARMA INC (INBP) does not currently pay a regular dividend.
Based on historical P/E analysis, INTEGRATED BIOPHARMA INC (INBP) appears expensive. The current P/E of 8.0 is 109% above its historical median of 3.8. The estimated fair value CAGR (P/E method) is -27.6%.
INTEGRATED BIOPHARMA INC (INBP) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
INTEGRATED BIOPHARMA INC (INBP) reported annual revenue of $54 million in its most recent fiscal year, based on SEC EDGAR filings.
INTEGRATED BIOPHARMA INC operates in the Pharmaceutical Preparations industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 52M | 54M | 50M | 51M | 56M | 64M |
| Net Income | -206K | 808K | 112K | -34K | 3.8M | 8.0M |
| EPS | $-0.01 | $0.03 | $0.00 | $-0.00 | $0.12 | $0.25 |
| Free Cash Flow | 2.8M | 1.9M | 390K | 1.1M | 3.6M | 2.8M |
| ROIC | -1.2% | 7.6% | 0.9% | 0.4% | 15.2% | 33.0% |
| Gross Margin | 7.8% | 10.2% | 7.7% | 8.0% | 11.6% | 14.9% |
| Debt/Equity | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | 0.25 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 577K | 2.0M | 251K | 120K | 2.7M | 5.8M |
| Operating Margin | 1.1% | 3.7% | 0.5% | 0.2% | 4.9% | 9.1% |
| ROE | -1.0% | 4.1% | 0.6% | -0.2% | 20.7% | 55.9% |
| Shares Outstanding | 31M | 27M | 31M | 30M | 32M | 32M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 34M | 37M | 42M | 47M | 44M | 50M | 53M | 64M | 56M | 51M | 50M | 54M | 52M |
| Gross Margin | 14.5% | 11.7% | 13.0% | 14.2% | 11.4% | 12.4% | 12.7% | 14.9% | 11.6% | 8.0% | 7.7% | 10.2% | 7.8% |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | 3.5M | 3.5M | 3.4M | 3.5M | 3.3M | 3.5M | 3.5M | 3.7M | 3.8M | 3.9M | 3.6M | 3.5M | 3.5M |
| EBIT | 1.4M | 933K | 2.1M | 3.2M | 1.7M | 2.7M | 3.3M | 5.8M | 2.7M | 120K | 251K | 2.0M | 577K |
| Op. Margin | 4.0% | 2.5% | 5.0% | 6.8% | 3.9% | 5.4% | 6.2% | 9.1% | 4.9% | 0.2% | 0.5% | 3.7% | 1.1% |
| Net Income | 131K | 735K | 958K | 2.3M | 679K | 1.7M | 4.1M | 8.0M | 3.8M | -34K | 112K | 808K | -206K |
| Net Margin | 0.4% | 2.0% | 2.3% | 5.0% | 1.6% | 3.4% | 7.8% | 12.6% | 6.8% | -0.1% | 0.2% | 1.5% | -0.4% |
| Non-Recurring | 4K | 3K | 15K | 0 | 5K | 0 | 2.6M | 2.6M | 2.6M | 2.6M | 0 | 28K | 28K |
| Returns on Capital | |||||||||||||
| ROIC | 6.7% | 6.8% | 13.3% | 21.9% | 7.7% | 21.2% | 24.0% | 33.0% | 15.2% | 0.4% | 0.9% | 7.6% | -1.2% |
| ROE | -1.3% | -7.5% | -10.9% | -32.9% | -12.2% | 89.2% | 67.7% | 55.9% | 20.7% | -0.2% | 0.6% | 4.1% | -1.0% |
| ROA | 1.1% | 6.3% | 7.5% | 16.1% | 4.6% | 8.5% | 17.9% | 31.5% | 15.2% | -0.1% | 0.4% | 3.2% | -0.9% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 1.9M | -113K | -594K | 397K | 1.2M | 328K | 1.3M | 3.1M | 4.1M | 1.2M | 943K | 2.1M | 3.1M |
| Free Cash Flow | 1.7M | -348K | -703K | 70K | 921K | -86K | 1.1M | 2.8M | 3.6M | 1.1M | 390K | 1.9M | 2.8M |
| Owner Earnings | 1.5M | -622K | -976K | -45K | 806K | -137K | 968K | 2.5M | 3.4M | 561K | 384K | 1.6M | 2.6M |
| CapEx | 182K | 235K | 109K | 327K | 247K | 414K | 214K | 295K | 486K | 116K | 553K | 205K | 303K |
| Maint. CapEx | 390K | 405K | 351K | 393K | 348K | 321K | 312K | 337K | 336K | 351K | 307K | 318K | 302K |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 93K | 0 | 0 | 150K | 0 | 246K | 0 | 0 |
| D&A | 390K | 405K | 351K | 393K | 348K | 321K | 312K | 337K | 336K | 351K | 307K | 318K | 302K |
| CapEx/OCF | N/A | N/A | N/A | 82.4% | 21.1% | 126.2% | 16.0% | 9.7% | 11.9% | 9.4% | 58.6% | 9.9% | 9.7% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 0 | 104K | 31K | 49K | 14K | 144K | 59K | 231K | 369K | 320K | 252K | 185K | 180K |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | 4.5M | 4.6M | 5.7M | 5.2M | 4.2M | 8.7M | 7.5M | 3.2M | -476K | -2.5M | -3.3M | -7.0M | -5.2M |
| Cash & Equiv. | 451K | 71K | 395K | 132K | 228K | 475K | 402K | 210K | 331K | 1.3M | 1.7M | 3.6M | 5.3M |
| Long-Term Debt | 4.4M | 3.9M | 5.2M | 4.2M | 3.6M | 2.7M | 1.4M | 0 | 53K | 7K | 0 | 115K | 92K |
| Debt/Equity | -0.49 | -0.50 | -0.74 | -0.90 | -0.84 | 5.07 | 1.37 | 0.25 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 |
| Interest Coverage | 1.4 | 1.0 | 2.2 | 3.5 | 1.8 | 4.3 | 8.2 | 22.6 | 21.4 | 8.6 | 13.9 | 51.8 | 51.8 |
| Equity | -10M | -9.3M | -8.3M | -5.9M | -5.2M | 1.9M | 6.1M | 14M | 19M | 19M | 19M | 20M | 20M |
| Total Assets | 12M | 12M | 14M | 15M | 15M | 20M | 23M | 25M | 25M | 25M | 26M | 25M | 24M |
| Total Liabilities | 22M | 21M | 22M | 21M | 20M | 18M | 17M | 11M | 6.7M | 6.6M | 7.0M | 4.6M | 3.8M |
| Intangibles | 880K | 743K | 235K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -55M | -54M | -53M | -51M | -50M | -48M | -44M | -36M | -32M | -32M | -32M | -31M | -32M |
| Working Capital | -2.5M | -2.5M | 246K | 1.4M | -3.9M | 1.7M | 3.4M | 8.8M | 11M | 12M | 12M | 15M | 14M |
| Current Assets | 9.2M | 9.3M | 12M | 13M | 12M | 14M | 16M | 18M | 17M | 16M | 18M | 19M | 18M |
| Current Liabilities | 12M | 12M | 12M | 11M | 16M | 12M | 13M | 9.2M | 5.3M | 4.8M | 6.1M | 4.2M | 3.5M |
| Per Share Data | |||||||||||||
| EPS | 0.01 | 0.02 | 0.05 | 0.10 | 0.02 | 0.06 | 0.13 | 0.25 | 0.12 | -0.00 | 0.00 | 0.03 | -0.01 |
| Owner EPS | 0.11 | -0.02 | -0.05 | -0.00 | 0.02 | -0.00 | 0.03 | 0.08 | 0.11 | 0.02 | 0.01 | 0.06 | 0.08 |
| Book Value | -0.78 | -0.25 | -0.43 | -0.25 | -0.15 | 0.07 | 0.19 | 0.45 | 0.58 | 0.63 | 0.62 | 0.75 | 0.64 |
| Cash Flow/Share | 0.14 | -0.00 | -0.03 | 0.02 | 0.03 | 0.01 | 0.04 | 0.10 | 0.13 | 0.04 | 0.03 | 0.08 | 0.00 |
| Dividends/Share | 0.00 | 0.00 | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 13.1M | 36.8M | 19.2M | 23.5M | 34.0M | 28.1M | 31.6M | 32.1M | 32.0M | 30.1M | 31.1M | 26.9M | 31.1M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | 1.9 | 6.5 | 3.8 | 3.7 | 4.4 | 3.8 | N/A | N/A | 11.0 | -26.2 |
| P/FCF | N/A | N/A | N/A | 63.7 | 4.8 | N/A | 13.5 | 12.8 | 4.1 | 8.9 | 16.7 | 4.8 | 1.8 |
| EV/EBIT | N/A | N/A | N/A | 3.0 | 5.1 | 3.6 | 5.8 | 6.3 | 5.3 | 71.9 | 19.3 | 2.7 | -0.3 |
| Price/Book | N/A | N/A | N/A | N/A | N/A | 3.4 | 2.5 | 2.5 | 0.8 | 0.5 | 0.3 | 0.4 | 0.3 |
| Price/Sales | N/A | N/A | N/A | 0.1 | 0.1 | 0.1 | 0.2 | 0.4 | 0.5 | 0.2 | 0.2 | 0.1 | 0.1 |
| FCF Yield | N/A | N/A | N/A | 1.6% | 20.9% | -1.3% | 7.4% | 7.8% | 24.5% | 11.2% | 6.0% | 20.9% | 56.7% |
| Market Cap | 0 | 0 | 0 | 4.5M | 4.4M | 6.5M | 15M | 35M | 15M | 9.9M | 6.5M | 8.9M | 5.0M |
| Avg. Price | 0.00 | 0.00 | 0.00 | 0.18 | 0.18 | 0.15 | 0.30 | 0.77 | 0.94 | 0.42 | 0.26 | 0.28 | 0.16 |
| Year-End Price | 0.00 | 0.00 | 0.00 | 0.19 | 0.13 | 0.23 | 0.48 | 1.10 | 0.46 | 0.33 | 0.21 | 0.33 | 0.16 |
INTEGRATED BIOPHARMA INC passes 2 of 9 quality checks, indicating weak fundamentals.
INTEGRATED BIOPHARMA INC trades at 8.0x trailing earnings, compared to its 15-year median P/E of 3.8x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 2.1x vs a median of 10.8x. The company's 5-year average ROIC is 11.4% with a gross margin of 10.5%. At current prices, the estimated annualized return to fair value is +14.1%.
INTEGRATED BIOPHARMA INC (INBP) has a net profit margin of 1.5%. This is a modest margin.
INTEGRATED BIOPHARMA INC (INBP) generated $2 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
INTEGRATED BIOPHARMA INC (INBP) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
INTEGRATED BIOPHARMA INC (INBP) reported earnings per share (EPS) of $0.03 in its most recent fiscal year.
INTEGRATED BIOPHARMA INC (INBP) has a return on equity (ROE) of 4.1%. This indicates moderate shareholder returns.
INTEGRATED BIOPHARMA INC (INBP) has a 5-year average gross margin of 10.5%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 15 years of financial data for INTEGRATED BIOPHARMA INC (INBP), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
INTEGRATED BIOPHARMA INC (INBP) has a book value per share of $0.75, based on its most recent annual SEC filing.
No recent press releases.